06 dec: 29% fortryder efterløn
09 dec: Skandalen ingen taler om
06-12-2010 19:17:00

Bloomberg plans to build new European HQ in London

Relateret indhold

LONDON (Reuters) - Global news agency and media group Bloomberg said a new European headquarters designed by Norman Foaster and set to be built on a site near the Bank of England should be completed in 2015.

U.S.-based property developer Tishman Speyer will be development manager on the project -- two buildings on a 3.2-acre site close to Bloomberg's existing European HQ.

The Financial Times reported Bloomberg had signed a deal to buy the site from Legal and General (Legal & General Group PLC).

When completed, Bloomberg will occupy one of the 500,000 square feet office blocks, while the second will be a "speculative building," it said. Speculative buildings are those for which no occupants have been identified.

A Bloomberg spokeswoman declined to comment on the sum paid for the new site, and said it has yet to make plans for the second building, or for the company's existing London offices near Moorgate.

Bloomberg's current London headquarters on Finsbury Square, part of which was also designed by Foster, has served as the company's European headquarters since 1987 and currently houses over 2,300 employees, it said.

Major developers including British Land (British Land Company PLC ORD 2), Hammerson (Hammerson PLC ORD 25P) and Land Securities (Land Securities Group PLC ORD) have unveiled plans to build new office buildings in London in recent months, stirring industry concerns of a potential oversupply as Britain's economic recovery remains weak.

(Reporting by Daryl Loo; Editing by Dan Lalor)

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo-rival spår effekt af ugentligt GLP-1 på linje med Ozempics

13-12-2017 13:30:09
Novo Nordisks store franske rival Sanofi forudser, at dens ugentlige GLP-1-analog, Efpeglenatid, har en effekt på langtidsblodsukkeret, der er på linje Novos nye ugentlige diabetes 2-middel Ozempic, som tilhører samme lægemiddelklasse.Det fremgår af en præsentation under et analytikerarrangement onsdag, hvor Sanofi fremlægger sin forsknings- og udviklingsstrategi for de kommende år.Sanofi indledte..

Novo-rival er på vej med nye studier i fedme og leversygdommen NASH

13-12-2017 09:56:25
Novo Nordisks store franske rival, Sanofi, vil ligesom Novo i de kommende år også fokusere på udviklingen af fedmemedicin og medicin til behandling af leversygdommen, NASH.Det fremgår af en pressemeddelelse i forbindelse med et analytikerarrangement onsdag, hvor Sanofi vil præsentere sin forsknings- og udviklingsstrategi for de kommende år.Sanofis udviklingsindsats inden for forretningsområdet, di..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får sin største ordre nogensinde i Indien - NY
2
Vestas rykker nærmere kæmpekontrakter i New Mexico og Texas
3
Aktier/tendens: Genmab og Vestas fortsætter i fokus
4
Vestas ejer mere end 5 pct. egne aktier efter opkøb
5
Onsdagens aktier: Genmab endnu engang til bunds i negativt marked

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
14. december 2017 03:31:19
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-14 03:31:19 - 2017-12-14 03:31:19 - 1 - Website: OKAY